Erlotinib Prevention of Oral Cancer (EPOC).

Trial Profile

Erlotinib Prevention of Oral Cancer (EPOC).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Orofacial cancer
  • Focus Therapeutic Use
  • Acronyms EPOC
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 22 Sep 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 14 Mar 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top